

PRESS BOOK

Preclinical Research Papers and Posters

A GLOBAL SERVICE PROVIDER OF PRECLINICAL AND CLINICAL RESEARCH IN OPHTHALMOLOGY

Modulation of inflammation-related genes in the cornea of a mouse model of dry eye upon treatment with cyclosporine eye drops#2019-222

DAULL P (a), BARABINO S (b), **FERAILLE L** (c), KESSAL K (d), DOCQUIER (e), PARSADANIANTZ S (d), BAUDOUIN C (d,f), and GARRIGUE JS (a)

Curr. Eye Res. 2019 Jan 21:1-10. doi: 10.1080/02713683.2018.1563197

(a) SANTEN SAS, Evry, France - (b) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy - (c) IRIS PHARMA, La Gaude, France - (d) INSTITUT DE LA VISION, Paris, France - (e) iGE3 Genomics Platform, University of Geneva, Switzerland - (f) Quinze-Vingts National Ophthalmology Hospital, Paris, France



Chronic model of uveitis in rabbit - Efficacy of triamcinolone acetonide#2019-221

QUENTRIC Y (a), **ANTONELLI S** (a), **MAURO V** (a), **CIMBOLINI N** (a), **FERAILLE L** (a), and **ELENA PP** (a)

ARVO meeting 2019; Vancouver - CANADA. Abstract No. 800 - B0278

(a) IRIS PHARMA, La Gaude, France



Efficacy of preservative-free cyclosporine emulsion eye drops in a mouse model of dry eye#2019-220

DAULL P (a), NAGANO T (b), OKADA S (b), **GROS E** (c), **FERAILLE L** (c), and GARRIGUE JS (a)

ARVO meeting 2019; Vancouver - CANADA. Abstract No. 292 - B0431

(a) SANTEN SAS, Evry, France - (b) SANTEN Ltd., Osaka, Japan - (c) IRIS PHARMA, La Gaude, France



Dry Eye: efficacy evaluation of two synthetic peptides from chondrocyte derived extracellular matrix (CDEM) in comparison to lifitegrast, cyclosporine A, diquafosol sodium and sodium hyaluronate in a murine model of dry eye#2019-219

BAIK T (a), CHOI J (a), MIN K (a), **FERAILLE L** (b), **RAYMOND E** (b), and **ELENA PP** (b)

ARVO meeting 2019; Vancouver - CANADA. Abstract No. 291 - B0430

(a) YUYU PHARMA, Seoul, The Republic of Korea - (b) IRIS PHARMA, La Gaude, France



Comparison of inflammatory gene networks in dry eye between human and mouse#2019-218

KESSAL K (a,b), DAULL P (c), **FERAILLE L** (d), **CIMBOLINI N** (d), LIANG H (a,b), DOCQUIER (e), BARABINO S (f), MELIK PARSADANIANTZ S (a), GARRIGUE JS (c), BAUDOUIN C (a,b), and BAUDOUIN F (a,b)

ARVO meeting 2019; Vancouver - CANADA. Abstract No. 274 - B0413

(a) INSTITUT DE LA VISION, Paris, France - (b) Quinze-Vingts National Ophthalmology Hospital, Paris, France - (c) SANTEN SAS, Evry, France - (d) IRIS PHARMA, La Gaude, France - (e) iGE3 Genomics Platform, University of Geneva, Switzerland - (f) CLINICA OCULISTICA, Genova, Italy



Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study#2019-217

ECONOMOU M (a), KOLSTAD LAUKELAND H (b,c), GRABSKA-LIBEREK I (d), and ROULAND JF (e)

Clinical Ophthalmol. 2018; 12: 2399–2407 (collaboration)

(a) St Erik's Eye Hospital, Stockholm, Sweden - (b) University Hospital, Trondheim, Norway - (c) Norwegian University of Science and Technology, Trondheim, Norway - (d) Ophthalmology Clinic Postgraduate Centre of Medical Education, Warszawa, Poland - (e) Claude Huriez Hospital, Lille, France



Safety and tolerability of overdosed artificial tears by abraded rabbit corneas#2018-215

DAULL P (a), **RAYMOND E** (b), **FERAILLE L** (b), and GARRIGUE JS (a)

J. Ocul. Pharmacol. Ther. 2018; DOI: 10.1089/jop.2018.0040

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France



The uni-nephrectomized SDT fatty rat, a novel type 2 diabetic model of diabetic nephropathy, develops features of diabetic retinopathy over 10 weeks#2018-214

BRIAND F (a), **ANTONELLI S** (b), **MAURO V** (b), **CIMBOLINI N** (b), SHINOHARA M (c), BROUSSEAU E (a), OHTA T (d), KAGEYAMA Y (c), **FERAILLE L** (b), and SULPICE T (a)

ARVO meeting 2018; Hawaii - USA. Abstract No. 3573 - A0190

(a) PHYSIOGENEX, Labege, France - (b) IRIS PHARMA, La Gaude, France - (c) CLEA Japan Inc., Tokyo, Japan - (d) JAPAN TOBACCO Inc., Osaka, Japan



Safety evaluation of cationic emulsions following refractive surgery procedures#2017-207

QUENTRIC Y (a), DAULL P (b), **GROS E** (a), **ANTONELLI S** (a), **MAURO V** (a), **FERAILLE L** (a), and GARRIGUE JS (b)

ARVO meeting 2017; Baltimore - USA. ARVO e-abstract No. 5297 - Poster B0250

(a) IRIS PHARMA, La Gaude, France - (b) NOVAGALI Innovation Center, SANTEN SAS, Evry, France



Exploratory ocular surface distribution studies of azithromycin formulations based on semifluorinated alkanes#2017-213

FISCHER K (a), GRILLENBERGER R (a), **AMAR T** (b), and KRÖSSER S (a)

EVER meeting 2017; Nice, France. Acta Ophthalmologica. DOI: 10.1111/j.1755-3768.2017.OS029

(a) NOVALIQ GmbH, 69120 Heidelberg, Germany - (b) IRIS PHARMA, La Gaude, France



Comparative efficacy of preservative-free anti-inflammatory eye drops in a mouse model of dry eye#2017-210

GARRIGUE JS (a), **CIMBOLINI N** (b), KESSAL K (c), **GROS E** (b), **MAURO V** (b), BARABINO S (d), BAUDOUIN C (c), and DAULL P (a)

ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8): 800. doi:

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) INSTITUT DE LA VISION, Paris, France - (d) CLINICA OCULISTICA, Genoa, Italy



Oral administration of the 11 β -hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study#2017-212

SCHWAB D (a), STURM C (a), PORTRON A (a), FUERST-RECKTENWALD S (b), HAINZL D (c), JORDAN P (d), STEWART W (e), TEPEDINO M (f), and DUBINER H (g)

BMJ Open Ophthalm 2017;1:e000063. DOI: 10.1136/bmjophth-2016-000063 (collaboration)

(a) ROCHE INNOVATION CENTER, Clinical Pharmacology, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (b) ROCHE INNOVATION CENTER, Translational Medicine, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (c) ROCHE INNOVATION CENTER, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (d) Department of Biometrics, Product development, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (e) PRN Pharmaceutical Research Network, LLC, Cheyenne, Wyoming, USA - (f) Cornerstone Eye Care, Division of Health Care, High Point, North Carolina, USA - (g) Eye Care Centers Management, Inc., Clayton Eye Center, Morrow, Georgia, USA



Binding to ocular albumin as a half-life extension. Principle for intravitreally injected drugs: evidence from mechanistic rat and rabbit studies#2017-206

FUCHS H (a), and IGNEY F (a)

J. Ocul. Pharmacol. Ther. 2017; DOI: 10.1089/jop.2016.0083 (collaboration)

(a) BOEHRINGER INGELHEIM PHARMA GmbH & Co. KG, Biberach an der Riss, Germany

Transform your microscope into an ultramicroscope for 3D imaging of cleared organs#2017-211

GESSION M (a), **KECHAD M** (b), MAUCLERT N (c), GIRARD P (c), ROUSSEL A (c), PIERRE O (d), GROSJEAN I (e), and BRAU F (f)

Focus on Microscopy meeting 2017; Bordeaux - France. Poster No P2-A/26

(a) CNRS, INSERM, Institut Biologie Valrose, Nice, France - (b) IRIS PHARMA, La Gaude, France - (c) OCA, Service de Mécanique Mutualisé, France - (d) IINRA, Institut Sophia Agrobiotech, Biot, France - (e) INSERM, Institut de Recherche sur le Cancer et le Vieillessement, Nice, France - (f) CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France

Conditional self-knockout of otx2 mice: a new model for late-onset neuronal degeneration#2017-209

ELENA PP (a), **ANTONELLI S** (a), **MAURO V** (a), **CIMBOLINI N** (a), LAMONERIE T (b), and **FERAILLE L** (a)

ARVO meeting 2017; Baltimore - USA. ARVO e-abstract No. 4532 - Poster B0187

(a) IRIS PHARMA, La Gaude, France - (b) UNIVERSITE DE NICE, Nice, France



Corneal transcriptome changes in a mouse model of dry eye#2017-208

DAULL P (a), **FERAILLE L** (b), KESSAL K (c), **ELENA PP** (b), BARABINO S (d), BAUDOUIN C (c), and GARRIGUE JS (a)

ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8): 797. doi:

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) INSTITUT DE LA VISION, Paris, France - (d) CLINICA OCULISTICA, Genoa, Italy



Pre-clinical in vivo (animal) testing of ocular formulations and drug delivery systems#2016-200

ELENA PP (a)

Ocular Drug Delivery; Berlin - Germany. Oral communication

(a) IRIS PHARMA, La Gaude, France

Ocular tolerance in rabbits of intracameral administration of MYDRANE, a fixed combination of tropicamide, phenylephrine, and lidocaine for cataract surgery#2016-202

OLMIERE C (a), and VIAUD K (b)

EVER meeting 2016; Nice - France

(a) LABORATOIRES THEA, Clermont-Ferrand, France - (b) IRIS PHARMA, Nice, France



Norbixin protects retinal pigmented epithelium cells and photoreceptors against A2E-mediated phototoxicity in vitro and in vivo#2016-205

FONTAINE V (a), MONTEIRO E (a), BRAZHNIKOVA E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), and LAFONT R (b)

PLOS ONE 11(12): e0167793. doi: 10.1371/journal.pone.0167793

(a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France



SMA+ perivascular cells evaluation in VEGF induced blood-retinal barrier breakdown in rabbit model#2016-201

ELENA PP (a), MAURO V (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), VIAUD-QUENTRIC K (a), and FERAILLE L (a)

EVER meeting 2016; Nice - France

(a) IRIS PHARMA, La Gaude, France



BIO201: a new drug candidate for the treatment of dry AMD#2016-198

FONTAINE V (a), BRAZHNIKOVA E (a), MONTEIRO E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), and LAFONT R (b)

ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57: 1119. doi:

(a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France



Efficacy of a preservative-free cationic emulsion vehicle eye drop in a mouse model of dry eye#2016-223

QUENTRIC Y (a), DAULL P (b), FERAILLE L (a), ELENA PP (a), and GARRIGUE JS (b)

ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57: 422. doi:

(a) IRIS PHARMA, La Gaude, France - (b) NOVAGALI Innovation Center, SANTEN SAS, Evry, France



Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye#2016-204

DAULL P (a), FERAILLE L (b), BARABINO S (c), CIMBOLINI N (b), GRILLO-ANTONELLI S (b), MAURO V (b), and GARRIGUE JS (a)

Exp. Eye Res. 2016 Oct 21; 153:159-164

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy



Comparative efficacy of cyclosporine eye drop formulations in a mouse model of dry eye#2016-199

GARRIGUE JS (a), DAULL P (a), FERAILLE L (b), and BARABINO S (c)

ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57(12): 421. doi:

(a) SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy



Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping#2016-196

DAULL P (a), FERAILLE L (b), ELENA PP (b), and GARRIGUE JS (a)

J. Ocul. Pharmacol. Ther. 2016; DOI: 10.1089/jop.2015.0054

(a) SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France



Long-term tolerance of preservative-free eye drops containing macrogol hydroxystearate as an excipient#2015-197

Tolérance à long terme d'un collyre sans conservateur contenant comme excipient du macrogol hydroxystearate

VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a), and ELENA PP (a)

J. Fr. Ophtalmol. 2015; Doi : 10.1016/j.jfo.2015.09.011

(a) IRIS PHARMA, Nice, France



Efficacy evaluation of a cationic emulsion of cyclosporine in a mouse model of dry eye#2015-192

DAULL P (a), FERAILLE L (b), BARABINO S (c), and GARRIGUE JS (a)

ARVO meeting 2015; Denver, CO - USA. ARVO e-abstract No. 4468 - Poster A0094

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genova, Italy



Effects of the multi-kinase inhibitor regorafenib on ocular neovascularization#2015-191

KLAR J (d), BOETTGER M (a,d), FREUNDLIEB J (c), KELDENICH J (c), ELENA PP (b), and VON DEGENFELD G (d)

ARVO meeting 2015; DENVER, CO - USA. ARVO e-abstract No. 243 - Poster C0118

(a) Clinical Sciences Experimental Medicine, BAYER PHARMA AG, Wuppertal, Germany - (b) IRIS PHARMA, Nice, France - (c) BAYER PHARMA AG, Wuppertal, Germany - (d) Ophthalmology, BAYER PHARMA AG, Wuppertal, Germany



- Comparison of CKC- and BAK-cationic emulsions in a rat model of corneal wound healing**#2015-194
 DAULL P (a), **FERAILLE L** (b), **ELENA PP** (b), and GARRIGUE JS (a)
EVER meeting 2015; Nice – France. Poster T034
 (a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France
- Evaluation of a cyclosporine A ophthalmic ointment in an experimental mouse model of dry eye**#2015-193
CIMBOLINI N (a), **ANTONELLI S** (a), **MAURO V** (a), **FERAILLE L** (a), and **ELENA PP** (a)
EVER meeting 2015; Nice – France. Poster T031
 (a) IRIS PHARMA, La Gaude, France
- Comparison of the effect of dexamethasone and prednisolone acetate in a rat model of glucocorticoid-induced ocular hypertension following topical delivery**#2015-190
ELENA PP (a), **CIMBOLINI N** (a), **ANTONELLI S** (a), **BOUZIN M** (a), **FERAILLE L** (a), **VIAUD-QUENTRIC K** (a), NICOLAS MF (b), LAURENT S (c), and BLOT C (c)
ARVO meeting 2015; DENVER, CO - USA. ARVO e-abstract No. 2001 - Poster D0244
 (a) IRIS PHARMA, Nice, France - (b) SANOFI R&D - LGCR, Vitry-sur-Seine, France (c) SANOFI R&D - Ophthalmology Unit, Paris, France
- In vivo ocular tolerance of a new preservative-free eye drop formulation in rabbits**#2015-189
QUENTRIC Y (a), **VIAUD K** (a), **LEFRANC-JULLIEN S** (a), **FERAILLE L** (a), and **ELENA PP** (a)
ARVO meeting 2015; Denver, CO - USA. ARVO e-abstract No. 802 - Poster D0264.
 (a) IRIS PHARMA, Nice, France
- Cationic emulsion of cyclosporine for the management of ocular surface inflammation: a preclinical evaluation**#2015-195
 DAULL P (a), **FERAILLE L** (b), **AMRANE M** (a), **ELENA PP** (b), and GARRIGUE JS (a)
IOIS meeting 2015; San Francisco – USA
 (a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France
- HL036337 ophthalmic solution: topical TNF blocker for dry eye disease**#2015-216
Protein and AntiboPEGS meeting 2015 Boston, MA (collaboration)
 HanAll BioPharma Co., Ltd, Seoul, Korea
- Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation**#2014-224
 Invest. Ophthalmol. Vis. Sci 2014; 55: 2859. doi: (collaboration)
 TO-BBB TECHNOLOGIES BV, Leiden, Netherlands 
- Two simple animal models of intraocular pressure elevation for testing therapeutic drugs in glaucoma**#2014-187
GRILLO-ANTONELLI S (a), **CIMBOLINI N** (a), **FERAILLE L** (a), and **ELENA PP** (a)
EVER meeting 2014; Nice – France. Poster T017
 (a) IRIS PHARMA, Nice, France 
- The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye**#2014-188
BARABINO S (a), **ANTONELLI S** (b), **CIMBOLINI N** (b), **MAURO V** (b), and **BOUZIN M** (b)
 Invest. Ophthalmol. Vis. Sci. 2014; 55:6499-6504 doi:10.1167/iovs.14-14548
 (a) CLINICA OCULISTICA, GENOCA, ITALY - (b) IRIS PHARMA, Nice, France 
- Regulatory issues related to preclinical animal research**#2014-186
ELENA PP (a)
ARVO meeting 2014; Orlando, FL - USA. Oral communication
 (a) IRIS PHARMA, Nice, France
- Safety and tolerability of drugs within the suprachoroidal space in albino rabbits**#2014-183
PATEL S (a), **VERHOEVEN R** (a), **BURKE B** (a), **CACCIAMANI F** (b), **VIAUD-QUENTRIC K** (b), and **EDELHAUSER H** (c,a)
ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 4886 - Poster C0082
 (a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France - (c) EMORY UNIV EYE CENTER, Atlanta, GA, USA
- Plasma and ocular pharmacokinetic study comparing 3 µL micro-drop to typical 40 µL drop volume of timolol 0.5% in pigmented rabbits**#2014-185
VAN DER HEIDEN H (a,b), **AMAR T** (c), and **LICHTENAUEUR W** (a)
ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 453 - Poster D0072
 (a) MU-DROP, Apeldoorn, Netherlands - (b) ZAMB, Hospital Pharmacy, Tilburg, Netherlands - (c) IRIS PHARMA, Nice, France

Ocular pharmacokinetic study comparing ramipril and ramiprilat formulations administered orally or topically in pigmented rabbits#2014-184

QUENTRIC Y (a), **AMAR T** (a), **BARRE N** (a), **FERAILLE L** (a), and **REKIK R** (b)
ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 2360 - Poster B0036
IRIS PHARMA, Nice, France - (b) OPHTHALMOLOGY CLINIC, Tunis, Tunisia

Biocompatibility of MedinGel biodegradable drug delivery system in the eye#2014-182

SPIS M (a), **FERAILLE L** (b), **ANTONELLI S** (b), **CIMBOLINI N** (b), **ELENA PP** (b), **GAUDRIAULT G** (a), and **PETIT A** (a)
ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 5273 - Poster C0069
(a) MEDINCELL, Jacou, France - (b) IRIS PHARMA, Nice, France

Dry eye: two experimental rodent models for drug development#2013-181

CIMBOLINI N (a), **ANTONELLI S** (a), **BARABINO S** (b), **FERAILLE L** (a), **MARGARON P** (a), and **ELENA PP** (a)
TFOS meeting 2013; Taormina - Sicily - Italy
(a) IRIS PHARMA, Nice, France - (b) CLINICA OCULISTICA, Genova, Italy

Effects of cyclosporine in an experimental rat model of dry eye#2013-180

CIMBOLINI N (a), **ANTONELLI S** (a), **FERAILLE L** (a), **MARGARON P** (a), and **ELENA PP** (a)
EVER meeting 2013; Nice – France. Poster S008
(a) IRIS PHARMA, Nice, France

Impact of the routes of administration on the effects of cyclosporine in an experimental rat model of dry eye#2013-179

CIMBOLINI N (a), **GRILLO-ANTONELLI S** (a), **FERAILLE L** (a), **MARGARON P** (a), and **ELENA PP** (a)
ISOPT meeting 2013; Paris – France
(a) IRIS PHARMA, Nice, France

Suprachoroidal microinjection of triamcinolone acetonide is well tolerated in the albino rabbit#2013-177

VERHOEVEN R (a), **PATEL S** (a), **VIAUD-QUENTRIC K** (b), **CACCIAMANI F** (b), **AMAR T** (b), and **YERXA B** (a)
ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 119 - Poster C0124
(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA
(b) IRIS PHARMA, Nice, France

Comparison of two rodent models of dry eye induced by scopolamine#2013-176

ELENA PP (a), **CIMBOLINI N** (a), **ANTONELLI S** (a), **FERAILLE L** (a), **BARABINO S** (b), and **MARGARON P** (a)
ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 6002 - Poster A0065
(a) IRIS PHARMA, Nice, France
(b) CLINICA OCULISTICA, Genova, Italy

Assessment of a new device for conjunctival impression#2012-174

ROY P (a), **CIMBOLINI N** (b), **ANTONELLI S** (b), **FERAILLE L** (b), **ELENA PP** (b), and **BAUDOUIN C** (c)
MCLOSA meeting 2012; London - England
(a) OPIA Technologies, Paris, France - (b) IRIS PHARMA, Nice, France - (c) Ophthalmology, Quinze-Vingts Hospital, Paris, France

Protection of blue light induced retinal degeneration by the free radical scavenger phenyl-N-tert-butyl nitron and a serotonin receptor 5-HT_{1a} agonist in rats#2012-173

GRILLO-ANTONELLI S (a), **CIMBOLINI N** (a), **DUBOS H** (a), **FERAILLE L** (a), **MARGARON P** (a), and **ELENA PP** (a)
EVER meeting 2012; Nice - France. Poster S063
(a) IRIS PHARMA, Nice, France

Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping#2012-172

DAULL P (a), **FERAILLE L** (b), **ELENA PP** (b), **BAUDOUIN C** (c), and **GARRIGUE JS** (a)
EVER meeting 2012; Nice - France. Poster T036
(a) NOVAGALI PHARMA SA, Evry, France - (b) IRIS PHARMA, Nice, France - (c) INSTITUT DE LA VISION, Paris, France

Ocular surface effects of antiglaucoma combination therapies in a rat model of corneal scraping#2012-171

DAULL P (a), **GARRIGUE JS** (a), **FERAILLE L** (b), **BAUDOUIN C** (c), and **ELENA PP** (b)
EVER meeting 2012; Nice - France. Poster T037
(a) NOVAGALI PHARMA SA, Evry, France - (b) IRIS PHARMA, Nice, France - (c) INSTITUT DE LA VISION, Paris, France

Multiple topical administrations of Ramipril enhance retinal ganglion cell survival after transient retinal ischemia-reperfusion in rats#2012-170

ELENA PP (a), **VIAUD-QUENTRIC K** (a), **CHARFEDDINE R** (b), and **REKIK R** (c)
EVER meeting 2012; Nice - France. Poster F029
(a) IRIS PHARMA, Nice, France - (b) UNIMED, Sousse, Tunisie - (c) Ophthalmology Clinic, Tunis, Tunisia

Augmentation of the ocular penetration of dexamethasone with β -blocker and α -agonist co-administration#2012-169

ELENA PP (a), **SENSEBY F** (a), **BERMON F** (a), CHARFEDDINE R (b), and REKIK R (c)
EVER meeting 2012; Nice - France. Poster F107
(a) IRIS PHARMA, Nice, France - (b) UNIMED, Sousse, Tunisie - (c) Ophthalmology Clinic, Tunis, Tunisia



Anti-inflammatory effects of glucocorticoids on endotoxin-induced uveitis in rats: effects of the mode of administration#2012-168

ELENA PP (a), **CIMBOLINI N** (a), **ANTONELLI S** (a), DUBOS H (a), **FERAILLE L** (a), and **MARGARON P** (a)
ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6285 - Poster D 1145
(a) IRIS PHARMA, Nice, France



Assessment of intra-ocular pressure lowering effect of novel gel formulations of Latanoprost and Timolol in nonhuman primates following topical delivery#2012-167

GOODY RJ (a), WHITTAKER S (a), HENRY S (a), BROOKES R (a), STRUHARIK M (a), **BERMON F** (b), **MARGARON P** (b), **POLZER H** (c), and LAWRENCE MS (a)
ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1968 - Poster D 812
(a) RXGen, Hamden, CT - (b) IRIS PHARMA, Nice, France - (c) MEDPROJECT PHARMA, Bayern, Germany



Assessment of a new device for conjunctival impression#2012-166

ROY P (a), **CIMBOLINI N** (b), **ANTONELLI S** (b), **FERAILLE L** (b), **ELENA PP** (b), and BAUDOUIN C (c)
ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1868 - Poster A 331
(a) OPIA Technologies, Paris, France - (b) IRIS PHARMA, Nice, France - (c) Ophthalmology Quinze-Vingts Hospital, Paris, France



Assessment of a new device for conjunctival impression#2011-165

ROY P (a), **CIMBOLINI N** (b), **ANTONELLI S** (b), **FERAILLE L** (b), and **ELENA PP** (b)
ISOPT meeting 2011; Vienna, Austria (oral presentation)
(a) OPIA Technologies, Paris, France - (b) IRIS PHARMA, Nice, France

Evaluation of membrane material for impression cytology#2011-161

ROY P (a), **CIMBOLINI N** (b), **FERAILLE L** (b), **KECHAD M** (b), and **ELENA PP** (b)
ARVO meeting 2011; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1937 - Poster D 918
(a) OPIA Technologies, Paris, France - (b) IRIS PHARMA, Nice, France



Ocular distribution and spectrum of activity of a fully human anti-herpes simplex virus IgG Fab fragment, following topical application#2010-160

BERDUGO-POLAK M (a,b), LARSEN IV (c), ABADIE C (d), KOWALCZUK L (a,b), TOUCHARD E (a,b), NELSON JD (e), **ELENA PP** (f), BRANDT CR (c), BEHAR-COHEN F (a,b,g), and COMBETTE JM (d)
ARVO meeting 2010; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1991/ D1028
(a) INSERM UMRS 872, Paris, France - (b) Pierre et Marie Curie University, Paris, France - (c) University of Wisconsin School of Medicine and Public Health, Madison, WI - (d) ribOvax Biotechnologies, Petit-Lancy, Switzerland - (e) Calmune Corporation, San Diego, CA - (f) IRIS PHARMA, La Gaude, France - (g) Hotel-Dieu University Hospital, Paris, France

Designing dendrimers for ocular delivery#2010-157

SPATARO G (a,b), MALECAZE F (c), TURRIN CO (a,b), SOLER V (c), DUHAYON C(a,b), **ELENA PP** (d), MAJORAL JP (a,b), and CAMINADE AM (a,b)
Eur. J. Med. Chem. 2010; 45: 326-334
(a) CNRS, Laboratoire de Chimie de Coordination, Toulouse, France - (b) Université de Toulouse, Toulouse, France - (c) Hôpital Purpan, Toulouse, France - (d) IRIS PHARMA, Nice, France



Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation#2009-156

AKPEK EK (a), VITTITOW J (b), VERHOEVEN RS (b), BRUBAKER K (b), **AMAR T** (c), POWELL KD (d), BOYER JL (b), and CREAN C (b)
J. Ocul. Pharmacol. Ther. 2009; 25: 433-439
(a) THE WILMER EYE INSTITUTE, Johns Hopkins Hospital, Baltimore, USA - (b) INSPIRE Pharmaceuticals, Durham, USA - (c) IRIS PHARMA, Nice, France - (d) ENTHALPY ANALYTICAL, Durham, USA



Corneal effect of topical diclofenac co-administration with aminoside and steroid in rabbits#2009-154

CAILLAUD T (a), **VIAUD K** (a), and **ELENA PP** (a)
ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1957
(a) IRIS PHARMA, Nice, France

Snapshot test for investigating gels of anti-glaucoma compounds as topical formulations#2009-153

ELENA PP (a), **POLLIN C** (a), **BERMON F** (a), **AMAR T** (a), **CAILLAUD T** (a), and **POLZER H** (b)
ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6002
(a) IRIS PHARMA, Nice, France - (b) MEDPROJECT PHARMA, Bayern, Germany

Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits#2008-152

AMAR T (a), CAILLAUD T (a), and ELENA PP (a)
Curr Eye Res. 2008; 33: 149-158
 (a) IRIS PHARMA, Nice, France



Immunohistochemistry and in situ zymography to assess matrix metalloproteinases expression and activation by latanoprost in rat uveoscleral pathway#2008-149

ELENA PP (a), FRETON A (a), SPADAFORA A (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), FERAILLE L (a), and LAZDUNSKI M (b)
ARVO meeting 2008; Fort Lauderdale, FL - USA. ARVO e-abstract No. 2616
 (a) IRIS PHARMA, Nice, France - (b) IPMC-UMR 6097, Valbonne, France

Cationic oil-in-water emulsion as an improved cyclosporine ocular vehicle for vernal keratoconjunctivitis sicca (VKC)#2007-148

LAMBERT G (a), and RABINOVICH-GUILATT L (a)
ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO poster No. 2301/B999 (collaboration)
 (a) NOVAGALI PHARMA SA, Evry, France

Ocular tolerability of iontophoresis#2007-147

ROY P (a), ELENA PP (b), VIAUD K (b), CAILLAUD T (b), and CALIAS P
ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5800
 (a) EYEGATE Pharmaceuticals, Waltham, USA - (b) IRIS PHARMA, Nice, France

New evaluation techniques in ocular surface diseases: comparison of antiallergic drugs using in vivo confocal microscopy for assessing late response of induced ocular anaphylaxis in the guinea pig#2007-146

FERAILLE L (a)
 Oral presentation. **EVER meeting 2007**; Portoroz, Slovenia
 (a) IRIS PHARMA, Nice, France

Update on drug delivery systems used in the anterior part of the eye: review of the new drug delivery systems for the anterior chamber#2007-145

ELENA PP (a)
 Oral presentation. **ESCRS meeting 2007**; Stockholm, Sweden
 (a) IRIS PHARMA, Nice, France

In vivo characterization of the anti-inflammatory effect of a multikinase inhibitor targeting angiogenesis and inflammation#2007-141

JENSEN L (a), HJARNAA P (a), FENSHOLDT J (a), ELENA PP (b), ABELL K (a), and PETERSEN TK (a)
8th World Congress on Inflammation 2007; Copenhagen, Denmark. **Inflamm Res.** 2007; 56(suppl.3): S443, abstract P07.21
 (a) LEO PHARMA, Ballerup, Denmark - (b) IRIS PHARMA, Nice, France



The role of the CROs in the ophthalmological drug development in Europe#2006-140

ELENA PP (a)
 Oral presentation. **ISOPT meeting 2006**; Berlin, Germany
 (a) IRIS PHARMA, Nice, France

Pharmacokinetics of clonidine after a single application of transscleral iontophoresis in rabbits#2006-131

CAILLAUD T (a), ROY P (b), VIAUD K (a), and ELENA PP (a)
ARVO meeting 2006; Fort Lauderdale, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 2006; 47: ARVO e-abstract No. 5109
 (a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

Influence of solution composition and electrode design on transscleral iontophoresis delivery of dexamethasone disodium phosphate#2006-130

ROY P (a), VIAUD K (b), CAILLAUD T (b), and ELENA PP (b)
ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5110
 (a) EYEGATE, Paris, France - (b) IRIS PHARMA, Nice, France

Evaluation of ocular tolerability of repetitive corneal-scleral iontophoresis in pigmented rabbits#2006-129

ELENA PP (a), ROY P (b), VIAUD K (a), and CAILLAUD T (a)
ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5094
 (a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

Effects of dexamethasone in a rat model of choroidal neovascularization#2006-128

FERAILLE L (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), CAILLAUD T (a), and ELENA PP (a)
Ocular Anti-Angiogenesis meeting 2006; London - United Kingdom
 (a) IRIS PHARMA, Nice, France



- Variation of krüppel-like factors levels in mouse corneal model of angiogenesis**#2005-127
 CHIAMBARETTA F, DE GRAEVE F, **FERAILLE L**, NEZZAR H, MARCEAU G, DASTUGNE B, RIGAL D, **ELENA PP**, and SAPIN V
ARVO meeting 2005; Fort Lauderdale, FL. *Invest. Ophthalmol. Vis. Sci.* 2005; 46: ARVO e-abstract No. 2609
- Variation of krüppel-like factors ARNm levels in a mouse corneal model of angiogenesis**#2005-123
 CHIAMBARETTA F, NEZZAR H, **FERAILLE L**, DE GRAEVE F, MARCEAU G, **ELENA PP**, RIGAL D, DASTUGNE B, and SAPIN V
SFO meeting 2005; Paris – France. Abstract No. 380
- PKC412 reduces retinal neovascularization induced by hypoxic stimuli in pup mice**#2004-115
CAILLAUD T (a), **AMAR T** (a), OTTLE CZ A (b), WONG M (c), LAMBROU GN (b), and **ELENA PP** (a)
ARVO meeting 2004; Fort Lauderdale, FL - USA. *Invest. Ophthalmol. Vis. Sci.* 2004; 45: ARVO e-abstract No. 4062
 (a) IRIS PHARMA, Nice, France - (b) NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland - (c) NOVARTIS PHARMA, EAST HANOVER, USA
- PKC412 content in retina, choroid and plasma of pup mice with retinal neovascularization induced by hyperoxic stimuli**#2004-116
ELENA PP (a), **AMAR T** (a), **CAILLAUD T**(a), WONG M (b), and BIZEC JC (C)
ARVO meeting 2004; Fort Lauderdale, FL - USA. *Invest. Ophthalmol. Vis. Sci.* 2004; 45: ARVO e-abstract No. 4053
 (a) IRIS PHARMA, Nice, France - (b) NOVARTIS PHARMA, EAST HANOVER, USA - (C) NOVARTIS PHARMA AG, Basel, Switzerland
- In vivo and in vitro neurotoxicity of the human prion protein (PrP) fragment P118-135 independently of PrP expression**#2003-114
 CHABRY J, **RATSIMANOHATRA C**, SPONNE I, **ELENA PP**, VINCENT JP, and PILLOT T
J Neurosci. 2003 Jan 15; 23(2): 462-9
- Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits**#2001-113
 YERXA BR, DOUGLASS JG, **ELENA PP**, **CAILLAUD T**, **AMAR T**, REDICK CC, and PETERSON WM
Adv. Exp. Med. Biol. 2002; 506: 261-265
- Alginate effect on carteolol ocular pharmacokinetics in the pigmented rabbit**#2002-111
 TISSIE G, SEBASTIAN C, **ELENA PP**, DRIOT JY, and TRINQUAND C
J. Ocul. Pharmacol. Ther. 2002; 18: 65-73
- Topical ocular instillation of nitric oxide synthase inhibitors and intraocular pressure in rabbits**#2001-110
 FLEISCHHAUER JC, LIU R, **ELENA PP**, FLAMMER J, and HAEFLIGER IO
Klin. Monatsbl. Augenheilkd. 2001; 218: 351-353
- Ocular distribution of CAT-152 after a single subconjunctival injection in a pigmented rabbit model of glaucoma filtration surgery**#2001-108
ELENA PP, MCFARLANE S, GLOVER DR, **AMAR T**, and **CAILLAUD T**
ARVO meeting 2001; Fort Lauderdale, FL - USA. *Invest. Ophthalmol. Vis. Sci.* 2001; 42: S544, abstract No. 2915
- A new long acting ophthalmic formulation of carteolol containing alginate**#2000-106
 SECHOY O, TISSIE G, SEBASTIAN C, MAURIN F, DRIOT JY, and TRINQUAND C
Int. J. Pharm. 2000; **207**: 109-116. (collaboration)
- Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension**#2000-104
 LACHERETZ F, BARBIER A, SERRADEIL-LE GAL C, **ELENA PP**, MAFFRAND J, and LE FUR G
J. Ocul. Pharmacol. Ther. 2000; 16: 203-216
- Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits**#2000-103
 PISELLA PJ(a,b), FILLACIER K(d), **ELENA PP**(e), DEBBASCH C(b,c), and BAUDOIN C(a)
Ophthalmic Res. 2000; **32**: 3-8
 (a) Department of Ophthalmology, Ambroise Paré Hospital, APHP, Paris, France - (b) Toxicology Laboratory, University of Paris-V René Descartes, Paris, France - (c) Department of Cellular Pharmacotoxicology, XV-XX Hospital, Paris, France - (d) Department of Ophthalmology, University of Nice, France - (e) IRIS PHARMA, Nice, France
- Localisation of Venoruton in rat blood vessel after single oral administration**#2000-102
 SALLIN D, **ELENA PP** AND ZIJLSTRA J
14th World Congress of the 'Union Internationale de Phlebologie' Roma - Italy 2000
- Evaluation of a novel carteolol eye-drops with alginate as long action promoter** #2000-101
 TISSIE G, SEBASTIAN C, MAURIN F, SECHOY O, DRIOT JY, **ELENA PP**, and TRINQUAND C
EVER meeting 2000; Palma de Mallorca, Spain. *Ophthalmic Res.* 2000; 32(S2): 29, abstract No. 214

- Alginate acid effect on ocular distribution of carteolol after a single instillation in pigmented rabbits**#2000-100
SEBASTIAN C, TISSIE G, DRIOT JY, **ELENA PP**, and TRINQUAND C
EVER meeting 2000; Palma de Mallorca, Spain. **Ophthalmic Res.** 2000; 32(S2): 28, abstract No. 215
- Potency and duration of action of synthetic P2Y2-receptor agonists on schirmer scores in rabbits**#2000-99
YERXA BR, DOUGLASS JG, **ELENA PP**, **CAILLAUD T**, **AMAR T**, and PETERSON WM
(3rd International Conference on the Lacrimal Gland, Tear Film and Dry Eye Syndromes Maui, HI - USA) **Cornea** 2000; 19: S138
- Ethics committee recommendations for laboratory animals in private research in France**#2000-98
B. VERSCHUERE B, AUTISSIER C, DEGRYSE AD, GALLIX P, GOTTI B, LAURENT J, LEINOT M, and PEYCLIT I
Laboratory Animals 2000; 34: 236-243. (collaboration) 
- Benefits of a vasopressin V2 receptor antagonist, SR 121463, in the treatment of ocular hypertension in the rabbit**#1999-97
SERRADEIL-LE GAL C, LACHERETZ F, BARBIER A, **ELENA PP**, PASCAL M, MAFFRAND JP, and LE FUR G
World Congress on Neurohypophysial Hormones. 1999; Edinburgh – UK
- INS365, a P2Y2 receptor agonist, increases schirmer scores in albino rabbits**#1999-96
YERXA BR, **ELENA PP**, **CAILLAUD T**, **AMAR T**, and EVANS R
ARVO meeting 1999; Fort Lauderdale, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1999; 40: S540, abstract No. 2848
- Inflammation measurement and immunocharacterization of cell proliferation in an experimental model of proliferative vitreoretinopathy**#1998-95
BAUDOUIN C, KHOSRAVI E, PISELLA PJ, ETTAICHE M, and **ELENA PP**
Ophthalmic Res. 1998; 30: 340-350 
- The effect of pneumoperitoneum on intraocular pressure in rabbits with α -chymotrypsin-induced glaucoma**#1998-94
LENTSCHENER C, LEVEQUE JP, MAZOIT JX, and BENHAMOU D
Anesth. Analg. 1998; 86: 1283-1288. (collaboration)
- Activity of SR121463, a selective non-peptide vasopressine V2 receptor antagonist, in a rabbit model of glaucoma**#1998-93
LACHERETZ F, BARBIER A, SERRADEIL-LE GAL C, **ELENA PP**, MAFFRAND JP, and LE FUR G
(ISER 1998 Abstract No. 795; Paris - France) **Exp. Eye Res.** 1998; 67: S239
- Protective effect of nicardipine, a calcium channel blocker on electroretinogram and retinal cytoskeletal damages after ischemia-reperfusion on the rat**#1998-92
FREDJ-REYGRABELLET D, **CAILLAUD T**, and **ELENA PP**
ARVO meeting 1998; Fort Lauderdale, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1998; 39: S993, abstract No. 4591
- Comparison of efficacy between ketotifen and olopatadine eyedrops in allergic conjunctivitis**#1998-91
ELENA PP, **AMAR T**, FETZ A, and SCHOCH C
ARVO meeting 1998; Fort Lauderdale, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1998; 39: S549, abstract No. 2531
- Ocular distribution of lomefloxacin 0.3 % after a single instillation in the infected eye of pigmented rabbits**#1997-90
ELENA PP, and JAUCH A
J. Ocul. Pharmacol. Ther. 1997; 13: 551-558 
- Intraocular pressure effects of topical rilmenidine in ocular hypertensive animals and in healthy volunteers and glaucoma subjects**#1997-89
NORDMANN JP, **ELENA PP**, and VILAIN C
ISECOPP meeting 1997 Munich – Germany, p. 12
- Analyse de l'inflammation et de la prolifération cellulaire intra-oculaires dans un modèle expérimental de prolifération vitréorétinienne**#1997-87
PISELLA PJ, BECQUET F, **ELENA PP**, and BAUDOUIN C
Ophthalmologie (France) 1997; 11: 369-371
- Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits**#1997-86
TILLEUL P, DENIS P, MAIGNEN F, **ELENA PP**, NORDMANN JP, LEVERGE R, and ROSTENE W
Ophthalmic Res. 1997; 29: 218-226 

- Retinal damage and protection after ischemic injury in the rat: a reappraisal**#1997-85
ELENA PP, CAILLAUD T, AMAR T, and HARITON C
ARVO meeting 1997; Fort Lauderdale, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1997; 38: S888, abstract No. 4151
- Ocular distribution of Rescula® Eye-Drops in the pigmented rabbit after a single topical administration**#1997-84
CAILLAUD T, AMAR T, HARITON C, and ELENA PP
ARVO meeting 1997; Fort Lauderdale, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1997; 38: S815, abstract No. 3796
- Rilmenidine: effect on intraocular pressure in alpha-chymotrypsin rabbits**#1997-83
AMAR T, NORDMANN JP, CASTAGNE I, VILAIN C, and ELENA PP
ARVO meeting 1997; Fort Lauderdale, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1997; 38: S814, abstract No. 3790
- Protection induced by isopropyl unoprostone treatment after retinal ischemic injury in the rat**#1997-76
MOREL-MANDRINO P, CAILLAUD T, ELENA PP, and HARITON C
ARVO meeting 1997; Fort Lauderdale, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1997; 38: S103, abstract No. 502
- Antiproliferative activity of a liposomal delivery system of mitoxantrone on rabbit subconjunctival fibroblasts in an ex-vivo model**#1996-80
MAIGNEN F, TILLEUL P, BILLARDON C, XU-VAN OPSTAL WY, PELAPRAT D, ELENA PP, DENIS P, and ROSTENE W
J. Ocul. Pharmacol. Ther. 1996; 12: 289-298
- The renin-angiotensin system in the rabbit eye**#1996-79
RAMIREZ M, DAVIDSON EA, LUTTENAUER L, ELENA PP, CUMIN F, MATHIS GA, and DE GASPARO M
J. Ocul. Pharmacol. Ther. 1996; 12: 299-312
- Histological and cytological retinal changes after pressure-induced ischemia in rat eye**#1996-78
FREDJ-REYGRABELLET D, TABIASCO J, BALAS D, DENIS P, and ELENA PP
(JERMOV 1996 Abstract No. 399; Montpellier - France) Vision Res. 1996; 36: S220
- Pharmacokinetics of 0.1 % azelastine eyedrops, a histamine-H1-antagonist, with or without an induced allergic conjunctivitis**#1996-77
ELENA PP, KHOSRAVI E, BORBE H, HERBST M, and PETER G
ARVO meeting 1996; Fort Lauderdale, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1996; 37: S1027, abstract No. 4719
- Inflammation measurement and immunocharacterization of cell proliferation in experimental PVR**#1996-81
BAUDOUIN C, PISELLA PJ, KHOSRAVI E, ETTAICHE M, and ELENA PP
ARVO meeting 1996; Fort Lauderdale, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1996; 37: S391, abstract No. 1808
- Ocular bioavailability of ganciclovir gel, an anti-herpetic formulation, after topical administration to intact or removed corneal epithelium of rabbit eyes**#1996-74
KHOSRAVI E, ELENA PP, GOLDSCHMIDT P, and LUYCKX J
ARVO meeting 1996; Fort Lauderdale, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1996; 37: S81, abstract No. 383
- Allergic conjunctivitis and uveitis models: reappraisal with some marketed drugs**#1995-73
KHOSRAVI E, ELENA PP, and HARITON C
Inflamm. Res. 1995; 44: 47-54
- Lomefloxacin distribution after a single instillation in the infected eye of pigmented rabbits**#1995-69
KHOSRAVI E, ELENA PP, and JAUCH A
ISECOPP meeting 1995 Geneva - Switzerland, p. 67
- Non-invasive measurement of ocular temperature by using infrared thermographic analysis in immune and non-immune allergy models**#1995-68
ELENA PP, KHOSRAVI E, and HARITON C
ISECOPP meeting 1995 Geneva - Switzerland, p. 60
- The renin angiotensin system in the rabbit eye**#1995-67
RAMIREZ M, DAVIDSON EA, ELENA PP, MATHIS GA, and DE GASPARO M
ISECOPP meeting 1995 Geneva - Switzerland, p. 25
- Lack of cytotoxic effect of ganciclovir and acyclovir on rabbit corneal epithelial cells in vitro**#1995-66
KHOSRAVI E, ELENA PP, GOLDSCHMIDT P, BAUDOUIN C, and LUYCKX J
JERMOV meeting 1995; Montpellier - France. **Vision Res.** 1995; 35: S173, abstract No. P125
- Intraocular pressure effects of topical renin inhibitor CGP 38560 in normal and ocular hypertensive animals and in healthy volunteers and glaucoma subjects**#1995-72
NORDMANN JP, PERCICOT CL, ELENA PP, and MATHIS GA
ISECOPP meeting 1995; Geneva – Switzerland, p. 35



- Dimethindene maleate in allergic conjunctivitis: a new indication for an old drug**#1995-65
ELENA PP, KHOSRAVI E, and HARITON C
ARVO meeting 1995; Fort Lauderdale, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1995; 36: S1014, abstract No. 4699
- Central nervous system control of intraocular pressure**#1994-63
DENIS P, NORDMANN JP, ELENA PP, SARAUX H, and LAPALUS P
Fundam. Clin. Pharmacol. (France) 1994; 8: 230-237
- Correlation between anterior chamber inflammation and proliferative vitreoretinopathy – in the rabbit**#1995-64
KHOSRAVI E, BAUDOUIIN C, and ELENA PP
JERMOV meeting 1994; Montpellier - France, p 240, abstract No. P192
- Ocular distribution of nicergoline after intravenous administration in rats**#1994-62
ELENA PP, BERTHOLOM N, and KHOSRAVI E
JERMOV meeting 1994; Montpellier - France, p 173, abstract No. P12
- Topical sodium sucrose octasulphate reduces corneal lesions in a keratoconjunctivitis sicca model in the rat**#1994-61
CHIBRET H, ELENA PP, KHOSRAVI E, and FREDJ-REYGRABELLET D
ARVO meeting 1994; Sarasota, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1994; 35: 1693, abstract No. 2039
- Distribution of ganciclovir in the anterior uvea after topical application of 0.15 % ganciclovir gel to intact and HSV-infected eyes of rabbits**#1994-60
ELENA PP, GOLDSCHMIDT P, CHAST F, SAUVAGEON H, LUYCKX J, and KHOSRAVI E
ARVO meeting 1994; Sarasota, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1994; 35: 1682, abstract No. 1984
- Angiotensin-II antagonists reduce intraocular pressure by a combined effect on aqueous humor synthesis and outflow**#1994-58
MATHIS GA, PERCICOT C, MERMOUD A, and ELENA PP
ARVO meeting 1994; Sarasota, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1994; 35: 1483, abstract No. 1060
- Physiological roles of dopamine and neuropeptides in the retina**#1993-57
DENIS P, NORDMANN JP, ELENA PP, DUSSAILLANT M, SARAUX H, and LAPALUS P
Fundam. Clin. Pharmacol. (France) 1993; 7: 293-304
- Bioequivalence between timolol maleate formulated in ophthalmic solution (Timoptol®) and in a novel gel vehicle (T-Gel)**#1993-56
ELENA PP, POLZER H, and KHOSRAVI E
ARVO meeting 1993; Sarasota, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1993; 34: 1490, abstract No. 3902
- Ocular pharmacokinetics of topically-applied ganciclovir in rabbits with intact or removed corneal epithelium**#1993-55
CHIBRET H, ELENA PP, and KHOSRAVI E
ARVO meeting 1993; Sarasota, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1993; 34: 1050, abstract No. 1712
- Mifepristone (RU 486): in vitro binding to glucocorticoid receptors in iris-ciliary body and in vivo effects on intraocular pressure in rabbits**#1993-54
DENIS P, ELENA PP, NORDMANN JP, SARRIEAU A, SARAUX H, and ROSTENE W
ARVO meeting 1993; Sarasota, FL - USA. **Invest. Ophthalmol. Vis. Sci.** 1993; 34: 925, abstract No. 1115
- Piribédil : affinité pour les récepteurs dopaminergiques rétiniens et profil pharmacocinétique oculaire**#1993-53
LAPALUS P, DENIS P, DRICI M, FREDJ-REYGRABELLET D, and ELENA PP
J. Neur. 1993; 240 (Suppl 1): S17-S21
- Retinal dopaminergic receptor affinity and ocular pharmacokinetic profile of piribedil**#1992-52
LAPALUS P, DENIS P, DRICI M, FREDJ-REYGRABELLET D, and ELENA PP
J. Neurool. 1992; 239 (Suppl 1): S17-S21
- Ocular pharmacokinetics of trimetazidine in the pigmented rat after a single oral administration**#1992-51
ELENA PP, KHOSRAVI E, LAPALUS P, JOULIN Y, and HARPEY C
ISER meeting 1992; Stresa - Italy. **Exp. Eye Res.** 1992; 55: S55, abstract No. 184
- Effect of diclofenac sodium and diclofenac sodium SDU eyedrops on prostaglandin concentrations in aqueous humor of rabbits after extracapsular surgery**#1992-50
ELENA PP, ULRICH E, TSCHALÄR Y, LAPALUS P, ETTAICHE M, and KHOSRAVI E
ISER meeting 1992; Stresa - Italy. **Exp. Eye Res.** 1992; 55: S54, abstract No. 183

Ocular pharmacokinetics of two preservatives, benzalkonium chloride or benzoxonium chloride, after instillation in the pigmented rabbit#1992-49

ELENA PP, KHOSRAVI E, LAPALUS P, and ULRICH E
ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 182

Preclinical pharmacokinetics of the 14C-labelled aldose reductase inhibitor methosorbinil (E-0722)#1992-48

ELENA PP, KUNZ PA, and LAPALUS P
SOE meeting 1992, Brussels - Belgium, p. 188, abstract No. 737

La radioautographie en ophtalmologie : méthodologie et applications à l'étude des récepteurs oculaires et à l'hybridation in situ#1991-47

DENIS P, ELENA PP, NORDMANN JP, DUSSAILLANT M, LAPALUS P, SARAUX H, and ROSTENE W

"Physiologie, Pathologie et Génétique Oculaire." CHRISTEN Y AND DROIX-LEFAIX MT ed. (Springer Verlag, Paris, 1991), 105-113

Localisation et caractérisation radioautographiques des récepteurs β -adrénergiques oculaires dans les structures non pigmentées chez l'homme#1991-46

LAPALUS P, ELENA PP, NORDMANN JP, LAROCHE L, SARAUX H, and LAPALUS P
Ophthalmologie (France) 1991; 5: 53-56

Localization and characterization of substance P binding sites in rat and rabbit eyes#1991-45

DENIS P, FARDIN V, NORDMANN JP, ELENA PP, LAROCHE L, SARAUX H, and ROSTENE W
Invest. Ophthalmol. Vis. Sci. 1991; 32: 1894-1902



Autoradiographic characterization and localization of vasoactive intestinal peptide binding sites in albino rat and rabbit eyes#1991-44

DENIS P, DUSSAILLANT M, NORDMANN JP, ELENA PP, SARAUX H, and ROSTENE W
Exp. Eye Res. 1991; 52: 357-366

Autoradiographic localization of β -adrenergic binding sites in human retinal blood vessels#1991-43

DENIS P, ELENA PP, and LAPALUS P
Chibret Int. J. 1991; 7: 14-19

Distribution rétinienne des sites récepteurs dopaminergiques rétinien chez l'homme. Hypothèses fonctionnelles sur le rôle de la dopamine dans la vision#1991-42

DENIS P, NORDMANN JP, ELENA PP, and LAPALUS P
(Dopamine, Fonctions Cérébrales et Neurosensorielles; Budapest - Hungary 1991) Euthérapie

Autoradiographic localization of D1 and D2 dopamine binding sites in the human retina#1990-41

DENIS P, ELENA PP, NORDMANN JP, SARAUX H, and LAPALUS P
Neurosci. Lett. 1990; 116: 81-86

β -adrenergic binding sites in the human eye: an autoradiographic study#1990-40

ELENA PP, DENIS P, KOSINA-BOIX M, SARAUX H, and LAPALUS P
J. Ocul. Pharmacol. 1990; 6: 143-149

Localisation et caractérisation autoradiographiques de sites de liaison oculaires du VIP (Vasoactive Intestinal Peptide) chez le rat et le lapin albinos#1990-39

DENIS P, DUSSAILLANT M, ELENA PP, NORDMANN JP, ROSTENE W, and LAROCHE L
Ophthalmologie (France) 1990; 4: 30-32

Cytotoxicity studies in ophthalmology#1990-38

LAPALUS P, ETTAICHE M, FREDJ-REYGRABELLET D, JAMBOU D, and ELENA PP
Lens Eye Toxic Res. 1990; 7: 231-242

Ocular pharmacokinetics of ganciclovir gel after a single administration#1990-37

LAPALUS P, ETTAICHE M, LUYCKX J, and ELENA PP
AER meeting 1990, Bad Honnef - Germany, p 58, abstract No. 94

Hymecel pharmacokinetics after a single intracameral injection in phakic and aphakic eyes of pigmented rabbits#1990-36

ELENA PP, LAPALUS P, FREDJ-REYGRABELLET D, ETTAICHE M, and ULRICH E
AER meeting 1990, Bad Honnef - Germany, p 25, abstract No. 6

Specific receptors to vasculotropin in the eye#1990-35

MOUKADIRI H, DENIS P, ELENA PP, ROSTENE W, and PLOUET J
AER meeting 1990, Bad Honnef - Germany, p 24, abstract No. 4

- Localization and characterization of receptors in human and animal eyes by “in vitro” autoradiography**#1990-34
ELENA PP, DENIS P, FREDJ-REYGROBELLET D, ROSTENE W, and LAPALUS P
ISER meeting 1990, Helsinki - Finland, p 228, abstract No. 803
- Autoradiographic localisation of insuling binding sites in the human eye**#1990-33
DENIS P, **ELENA PP**, LE MARCHAND-BRUSTEL Y, NORDMANN JP, LAPALUS P, and SARAUX H
ISER meeting 1990, Helsinki - Finland, p 114, abstract No. 384
- Retinal dopaminergic receptors and distribution of piribedil**#1990-32
LAPALUS P, **ELENA PP**, FREDJ-REYGROBELLET D AND DENIS P
ENS meeting 1990, Brighton – UK
- Localisation et caractérisation radioautographiques des récepteurs β -adrénergiques oculaires dans les structures non pigmentées chez l'homme**#1990-31
DENIS P, **ELENA PP**, NORDMANN JP, SARAUX H, and LAPALUS P
SFO meeting 1990, Paris – France
- La radioautographie en ophtalmologie : méthodologie et applications à l'étude des récepteurs oculaires et à l'hybridation in situ**#1990-30
DENIS P, **ELENA PP**, NORDMANN JP, LAPALUS P, and SARAUX H
Séminaires Ophtalmologiques IPSEN, Royaumont - France 1990
- Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialized and intact rabbit eye**#1989-29
FREDJ-REYGROBELLET D, **ELENA PP**, MOENNER M, BAUDOUIN C, ETTAICHE M, BARRITAUULT D, and LAPALUS P
Curr. Eye Res. 1989; 8: 1141-1152
- Localisation autoradiographique des récepteurs dopaminergiques rétiniens chez l'homme. Implications fonctionnelles**#1989-28
DENIS P, NORDMANN JP, **ELENA PP**, LAROCHE L, and LAPALUS P
Bull. Soc. Ophtalmol. Fr. (France) 1989; 89: 807-810
- Récepteurs béta-adrenergiques vasculaires rétiniens chez l'homme**#1989-27
DENIS P, and **ELENA PP**
Ophtalmologie (France) 1989; 3: 62-64
- Dopamine receptors in rabbit and rat eye: characterization and localization of DA1 and DA2 binding sites**#1989-26
ELENA PP, DENIS P, KOSINA-BOIX M, and LAPALUS P
Curr. Eye Res. 1989; 8: 75-83
- Alpha2-adrenergic receptors in rat and rabbit eye: a tritium-sensitive film autoradiography**#1989-25
ELENA PP, KOSINA-BOIX M, DENIS P, MOULIN G, and LAPALUS P
Ophthalmic Res. 1989; 21: 309-314
- Localisation of angiotensin-converting enzyme (ACE) in rat ciliary process by autoradiography and immunocytochemistry**#1989-24
LALIBERTE F, **ELENA PP**, LALIBERTE MF, LAPALUS P, and CHEVILLARD C
AER meeting 1989, Montpellier - France, **Doc. Ophthalmol.** 1990; 76: 194-195, abstract No. 167
- Beta-adrenergic receptors in human eye sections**#1989-23
ELENA PP, DENIS P, LAROCHE L, and LAPALUS P
AER meeting 1989, Montpellier - France, **Doc. Ophthalmol.** 1990; 76: 194, abstract No. 166
- Autoradiographic localization of vasoactive intestinal peptide binding sites in albino rabbit and rat eye**#1989-22
DENIS P, DUSSAILLANT M, NORDMANN JP, **ELENA PP**, ROSTENE W, and SARAUX H
AER meeting 1989, Montpellier - France, **Doc. Ophthalmol.** 1990; 76: 159-160, abstract No. 104
- Autoradiographic localisation of insulin receptors in the human eye**#1989-21
ELENA PP, DENIS P, LE MARCHAND-BRUSTEL Y, and LAPALUS P
AER meeting 1989, Montpellier - France, **Doc. Ophthalmol.** 1990; 76: 158-159, abstract No. 102
- Pharmacokinetics of topically-administered aldose reductase inhibitor (E-0722) on pigmented rabbit eye**#1989-20
LAPALUS P, FREDJ-REYGROBELLET D, and **ELENA PP**
AER meeting 1989, Montpellier - France, **Doc. Ophthalmol.** 1990; 76: 129-130, abstract No. 45

Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialised and intact rabbit eye#1989-19

FREDJ-REYGRABELLET D, **ELENA PP**, MOENNER M, BAUDOIN C, ETTAICHE M, BARRITAULT D, and LAPALUS P
AER meeting 1989, Montpellier - France, **Doc. Ophthalmol.** 1990; 76: 111, abstract No. 13

Piribedil and retinal dopaminergic binding sites#1989-18

LAPALUS P, **ELENA PP**, DENIS P, and FREDJ-REYGRABELLET D
World Congress of Neurology 1989, New Dehli – India

Localisation autoradiographique des récepteurs dopaminergiques rétinien chez l'homme. Implications fonctionnelles#1989-17

DENIS P, NORDMANN JP, **ELENA PP**, LAROCHE L, and LAPALUS P
SFO meeting 1989, Paris – France

Neurotransmitters and intraocular pressure#1989-16

LAPALUS P, and **ELENA PP**
Fundam. Clin. Pharmacol. (France) 1988; 2: 305-325

Autoradiographic localization of beta-adrenergic binding sites in human blood retinal vessels#1988-15

ELENA PP, DENIS P, and LAPALUS P
ISER meeting 1988, San Francisco, CA – USA

Autoradiographic characterization of D-1 and D-2 receptors in rat, rabbit and human eyes#1988-14

ELENA PP, DENIS P, and LAPALUS P
ISER meeting 1988, San Francisco, CA – USA

Autoradiographic localization of β -adrenergic receptors in rabbit eye#1987-13

ELENA PP (a), KOSINA-BOIX M (b), MOULIN G (a), and LAPALUS P (b)
Invest. Ophthalmol. Vis. Sci. 1987; 28: 1436-1441
 (a) Laboratoires DULCIS ALLERGAN, Monaco - (b) the Laboratoire de Pharmacologie Faculte de Medecine, Nice, France



Dopamine DA1 receptors in the eye: characterization and localization of 125I-SCH 23982 binding sites#1987-12

ELENA PP, KOSINA-BOIX M, and LAPALUS P
AER meeting 1987, Leuven – Belgium

Effects of a new anti-allergic agent: the magnesium salt of N-Acetyl-Aspartyl-Glutamic Acid on experimental allergic inflammation of the rabbit eye#1986-11

LAPALUS P, MOULIN G, BAYER V, FREDJ-REYGRABELLET D, and **ELENA PP**
Curr. Eye Res. 1986; 5: 517-522

Monoclonal antibodies to human amnion recognize different components of the rabbit eye#1986-10

HSI BL, FREDJ-REYGRABELLET D, YEH CJG, **ELENA PP**, MOULIN G, and LAPALUS P
Invest. Ophthalmol. Vis. Sci. 1986; 27: 620-622



Système alpha-adrénergique et pression intra-oculaire#1986-9

LAPALUS P, and **ELENA PP**
Rencontres Internationales de Chimie Thérapeutique, Clermont-Ferrand - France 1986

Autoradiographic localization of β -adrenergic receptors in rabbit eye#1986-8

ELENA PP, KOSINA-BOIX M, MOULIN G, and LAPALUS P
AER meeting 1986, Oxford – UK

Embryological studies of rabbit eye by using monoclonal antibodies#1985-7

FREDJ-REYGRABELLET D, HSI BL, MOULIN G, YEH CJG, **ELENA PP**, and LAPALUS P
AER meeting 1985, Leyzin - Switzerland, p 61 abstract No. 73

Alpha-adrenoceptors in rabbit iris-ciliary-body (ICB) membranes: characterization and localization with 3H-clonidine#1985-6

ELENA PP, PALTRINIERI P, MOULIN G, FREDJ-REYGRABELLET D, and LAPALUS P
AER meeting 1985, Leyzin - Switzerland, p 5

Pharmacological characteristics of β -adrenergic-sensitive adenylate cyclase in non-pigmented and pigmented cells of bovine ciliary process#1984-5

ELENA PP, FREDJ-REYGRABELLET D, MOULIN G, and LAPALUS P
Curr. Eye Res. 1984; 3: 1383-1389

- Characterization of β -adrenergic receptors in bovine pigmented ciliary processes**#1984-4
ELENA PP, MOULIN G, and LAPALUS P
Curr. Eye Res. 1984; 3: 743-750
- Etude cinétique d'un anti-allergique, le 14C-T86 en instillation chez le lapin albinos**#1984-3
LAPALUS P, MOULIN G, BAYER V, **ELENA PP**, NICOLAS C, and LAPALUS F
J. Biophys. Med. Nucl. 1984; 8: 195-198
- Etude cinétique d'un anti-allergique, le 14C-T86, en instillation chez le lapin albinos**#1984-2
LAPALUS P, MOULIN G, BAYER V, **ELENA PP**, NICOLAS C, and LAPALUS F
Congrès de Médecine Nucléaire de Langue Française, Nice - France 1984
- Adenylate cyclase activity in non-pigmented (NPE) and in pigmented (PE) cells of bovine ciliary process**#1984-1
ELENA PP, FREDJ-REYGRBELLET D, MOULIN G, and LAPALUS P
ISER meeting 1984, Alicante - Spain, p 95

ABBREVIATIONS

ARVO	A ssociation for R esearch in V ision and O phthalmology
ATERET	A ssociation T unisienne d' E tude et de R echerche sur les E léments T race
ECLSO	E uropean C ontact L ens S ociety of O phthalmologists
EVER	E uropean V ision and E ye R esearch
IGS	I nternational G laucoma S ymposium
ISECOPP	I nternational S ymposium on E xperimental and C linical O cular P harmacology and P harmaceutics
ISOPT	I nternational S ymposium on O cular P harmacology and T herapeutics
MCLOSA	M edical C ontact L ens and O cular S urface A ssociation
SAFIR	S ociété de l' A ssociation F rançaise des I mplants et de la chirurgie R éfractive
SFERETE	S ociété F rancophone d' E tude et de R echerche sur les E léments T races T oxiques et E ssentiels
SFO	S ociété F rançaise d' O phthalmologie
SFVB	S ociété F rancophone V itamines et B iofacteurs